Colorectal Cancer

New Targeted Therapies for Metastatic Colorectal Cancer Recommended in the Updated NCCN Guideline

Wayne Kuznar

June 2019, Vol 10, No 3 - 2019 NCCN Conference, Colorectal Cancer

Orlando, FL—A growing number of targeted therapies and immunotherapies are now recommended in the updated National Comprehensive Cancer Network (NCCN) guideline for metastatic colorectal cancer (CRC). New first-line immunotherapy options for patients with mismatch repair deficiency (dMMR) and microsatellite instability-high (MSI-H) CRC are also listed in the new guideline. [ Read More ]

USPSTF Issues New Colorectal Cancer Screening Recommendations

Jessica Miller

July 2016, Vol 7, No 6 - Colorectal Cancer

New recommendations issued by the US Preventive Services Task Force (USPSTF) focus on increasing colorectal cancer screening, which, according to the task force, is “a substantially underused preventive health strategy.” Previous USPSTF guidelines recommended specific screening approaches, including colonoscopy, fecal occult blood testing, or sigmoidoscopy, for adults aged 50 through 75 years. [ Read More ]

Cologuard: Stool DNA Test Performs Well in Community-Based Setting Among Medicare Beneficiaries

Charles Bankhead

July 2016, Vol 7, No 6 - Colorectal Cancer

The multitarget stool DNA test, a noninvasive screening tool for colorectal cancer (CRC), demonstrated potential for identifying cancer and advanced adenomas in community-based individuals who had previously not followed national screening recommendations, reported Mark Prince, MD, MBA, Director of Gastroenterology, USMD Health System, Arlington, TX, at the 2016 American Association for Cancer Research annual meeting. [ Read More ]

In the Real World, Bevacizumab Improves Survival in Patients with Metastatic Colorectal Cancer

Wayne Kuznar

April 2014, Vol 5, No 3 - Colorectal Cancer

San Francisco, CA—In routine patient care, adding bevacizumab (Avastin) to standard FOLFIRI (leucovorin, 5-fluorouracil, and irinotecan) improves progression-free survival (PFS) and overall survival (OS) in patients with metastatic colorectal cancer (mCRC), according to data presented at the 2014 Gastrointestinal Cancers Symposium. [ Read More ]

New Colorectal Cancer Therapies Foster New Discussions on the Value of Medications

May 2010, Vol 1, No 1 - Colorectal Cancer

New chemotherapies for metastatic colon cancer have improved life expectancy, but at a significant cost, say the authors of a study that explores the value of medications including bevacizumab (Avastin, Genentech), capecitabine (Xeloda, Roche Laboratories), cetuximab (Erbitux, Bristol-Myers Squibb), irinotecan hydrochloride (Camptosar, Pfizer, Inc), and oxaliplatin (Eloxatin, Sanofi-Aventis LLC). [ Read More ]